Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2025-03-04
Summary
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Conditions
Interventions
- DRUG
-
oral tablet
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 12 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-24
- Primary Completion
- 2026-03-31
- Completion
- 2026-11-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
NCT00183612 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
NCT04712734 ·Status: COMPLETED ·Phase: PHASE1
-
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
NCT01190267 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
NCT01206517 ·Status: COMPLETED ·Phase: PHASE1
-
Olanzapine Treatment of Patients With Bipolar I Disorder
NCT00510146 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
NCT00510211 ·Status: COMPLETED
-
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
NCT01190254 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter, Open-label, Safety and Tolerability Study
NCT01649557 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo
NCT01920802 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
NCT00254202 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
NCT01429740 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Olanzapine in Patients With Schizophrenia
NCT00970281 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571 ·Status: COMPLETED ·Phase: PHASE4
-
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
NCT00094549 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine
NCT00194064 ·Status: TERMINATED ·Phase: PHASE3
-
Lurasidone Pediatric Pharmacokinetics Study
NCT01620060 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Safety Study in Adults With Schizophrenia
NCT02804568 ·Status: COMPLETED ·Phase: PHASE1
-
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCT00051298 ·Status: COMPLETED ·Phase: PHASE3
-
A First In Human Study Of PF-00184562 In Healthy Volunteers
NCT00150215 ·Status: COMPLETED ·Phase: PHASE1
-
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
NCT00050206 ·Status: COMPLETED ·Phase: PHASE4
-
Short Term Rescue Study of Olanzapine
NCT00186017 ·Status: COMPLETED ·Phase: PHASE4
-
Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)
NCT02287259 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)
NCT00156091 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
NCT03397134 ·Status: COMPLETED ·Phase: PHASE3
-
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044187 ·Status: COMPLETED ·Phase: PHASE4